Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.36 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL320653 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ATDP1LMNA | |
| SCHEMBL189622 | 0.75 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2ATDP1TSHR | |
| SCHEMBL5747160 | 0.73 | TDP1 (0.38) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL2090168 | 0.73 | CYP3A4 (0.46) | MEN1KMT2ATDP1RORCTSHR | |
| SCHEMBL1413983 | 0.72 | CYP3A4 (0.52) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL30600426 | 0.72 | ALDH1A1 (0.68) | ALDH1A1MEN1KMT2ATDP1LMNA | |
| SCHEMBL522436 | 0.72 | APOBEC3G (0.36) | ALDH1A1KDM4ELMNATSHR | |
| SCHEMBL2361509 | 0.70 | PDCD1 (0.36) | ALDH1A1LMNAHPGDRORC | |
| SCHEMBL21866036 | 0.70 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2ATDP1LMNA | |
| SCHEMBL8128591 | 0.69 | TSHR (0.50) | ALDH1A1MEN1KMT2ATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499577-B1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | HOFFMANN LA ROCHE (CH) | 2007-05-30 | — | — | EP | claimed |
| EP-1499577-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-26 | — | — | EP | claimed |
| US-6790852-B2 | HETEROCYCLIC NITROGEN COMPOUNDS SUCH AS 2-(2,6-DICHLOROPHENYL) -4-(3-BROMOPHENYL)-5-(2-(3- HYDROXYPROPYLAMINO)PYRIMIDIN-4-YL) -N-H-IMIDAZOLE, USED AS TYROSINE KINASE INHIBITORS; ANTICARCINOGENIC OR ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2004-09-14 | — | — | US | claimed |
| US-20030199691-A1 | 2-(2,6-dichlorophenyl)-diarylimidazoles | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | US | claimed |
| WO-2003087026-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | WO | claimed |
| EP-1499577-B1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | HOFFMANN LA ROCHE (CH) | 2007-05-30 | — | — | EP | disclosed |
| US-7144889-B2 | Triarylimidazoles | HOFFMAN-LA ROCHE INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1675848-A1 | NOVEL TRIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-05 | — | — | EP | disclosed |
| US-6946471-B2 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | HOFFMANN-LA ROCHE INC. (US) | 2005-09-20 | — | — | US | disclosed |
| WO-2005040153-A1 | NOVEL TRIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-20050085473-A1 | Novel triarylimidazoles | HOFFMANN-LA ROCHE INC. | 2005-04-21 | — | — | US | disclosed |
| EP-1499577-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-26 | — | — | EP | disclosed |
| US-20040214874-A1 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | BRANDT MICHAEL | 2004-10-28 | — | — | US | disclosed |
| US-6790852-B2 | HETEROCYCLIC NITROGEN COMPOUNDS SUCH AS 2-(2,6-DICHLOROPHENYL) -4-(3-BROMOPHENYL)-5-(2-(3- HYDROXYPROPYLAMINO)PYRIMIDIN-4-YL) -N-H-IMIDAZOLE, USED AS TYROSINE KINASE INHIBITORS; ANTICARCINOGENIC OR ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2004-09-14 | — | — | US | disclosed |
| US-20030199691-A1 | 2-(2,6-dichlorophenyl)-diarylimidazoles | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | US | disclosed |
| WO-2003087026-A1 | 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085473-A1 | Novel triarylimidazoles | AURKAIP1, GLS2, GOT2 | ALDH1A1 409/4885MEN1 1927/4885KMT2A 2396/4885 |
| US-20030199691-A1 | 2-(2,6-dichlorophenyl)-diarylimidazoles | CYP2D6, CYP2F1, CYP1A2 | ALDH1A1 115/4885MEN1 1726/4885KMT2A 933/4885 |
| US-20040214874-A1 | 2-(2,6-Dichlorophenyl)-Diarylimidazoles | CYP2D6, CYP1A2, CYP2F1 | ALDH1A1 89/4885MEN1 1918/4885KMT2A 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.